Dasatinib

Curated

← predicts response to

ABL1 Fusionfusion

5 source records aggregated

resistance

Curated

← predicts response to

ABL1 F317LSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 T315ISNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F317VSNV

resistance

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive

← predicts response to

ABL1 Fusionfusion

13 source records aggregated

resistance

Curated

← predicts response to

ABL1 Fusionfusion

3 source records aggregated

sensitivity

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive

← predicts response to

ABL1 Fusionfusion

3 source records aggregated

sensitivity

Curated

← predicts response to

ABL1 V299LSNV

2 source records aggregated

resistance

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive

← predicts response to

ABL1 E255KSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F359VSNV

2 source records aggregated

resistance

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive

← predicts response to

ABL1 T315ISNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 F317LSNV

resistance

Curated

← predicts response to

ABL1 L384MSNV

resistance

Curated

← predicts response to

ABL1 M351TSNV

resistance

Curated

← predicts response to

ABL1 G250ESNV

resistance

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

PDGFRB Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

PDGFRB Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 S438CSNV

resistance

Curated

← predicts response to

ABL1 D363GSNV

sensitivity

Curated

Lung Squamous Cell Carcinoma

← predicts response to

DDR2 S768RSNV

sensitivity

Curated

← predicts response to

KIT K642ESNV

sensitivity

Melanoma

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 Fusionfusion

29 source records aggregated

resistance

Curated

Acute Lymphoblastic Leukemia,Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 T315ISNV

7 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 Fusionfusion

5 source records aggregated

sensitivity

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 F317LSNV

3 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 F317VSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 V299LSNV

3 source records aggregated

resistance

Curated

← predicts response to

ABL1 E255KSNV

3 source records aggregated

resistance

Curated

Lung Non-Small Cell Carcinoma,Malignant Neoplasm,Melanoma

← predicts response to

KIT L576PSNV

3 source records aggregated

sensitivity

Curated

← predicts response to

ABL1 Q252HSNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F317ISNV

2 source records aggregated

resistance

Curated

Chronic Myeloid Leukemia, BCR-ABL1 Positive,Malignant Neoplasm

← predicts response to

ABL1 T315ASNV

2 source records aggregated

resistance

Curated

← predicts response to

ABL1 F317SSNV

resistance

Curated

← predicts response to

ABL1 E255KSNV

sensitivity

Curated

← predicts response to

ABL1 V299LSNV

sensitivity

Curated

← predicts response to

KIT D816VSNV

resistance

Curated

← predicts response to

ABL1 F317CSNV

resistance

Curated

← predicts response to

ARID1A P1175FS*5indel

sensitivity

—

Curated

← predicts response to

KIT S628NSNV

sensitivity

Curated

← predicts response to

ABL1 G398RSNV

sensitivity

Curated

← predicts response to

KIT V559DSNV

sensitivity

Curated

← predicts response to

ABL1 L248VSNV

resistance

Curated

← predicts response to

ABL1 H396PSNV

sensitivity

Curated

← predicts response to

ABL1 G250ESNV

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

resistance

Curated

← predicts response to

ABL2 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 Fusionfusion

sensitivity

Curated

← predicts response to

ABL1 L248RSNV

resistance

Curated

← predicts response to

ABL1 G340LSNV

sensitivity

Curated

Malignant Colorectal Neoplasm

← predicts response to

ARID1A Q456*SNV

sensitivity

Curated

← predicts response to

ARID1A Lossdeletion_cna

sensitivity

—

Curated

← predicts response to

ABCB1 Overexpressionexpression

resistance

Curated

Myeloid/Lymphoid Neoplasms with Eosinophilia and Tyrosine Kinase Gene Fusions

← predicts response to

PDGFRA Fusionfusion

sensitivity

Curated

Malignant Colorectal Neoplasm

← predicts response to

KRAS Mutationother

sensitivity

Curated

← predicts response to

DDR2 G774VSNV

sensitivity

Curated

← predicts response to

DDR2 G253CSNV

sensitivity

Curated

Intrahepatic Cholangiocarcinoma

← predicts response to

IDH1 R132

sensitivity

Curated

← predicts response to

ABL1 R351WSNV

sensitivity

Curated

← predicts response to

DDR2 L63VSNV

sensitivity

Curated

Lung Adenosquamous Carcinoma

← predicts response to

DDR2 L239RSNV

sensitivity

Curated

Lung Squamous Cell Carcinoma

← predicts response to

DDR2 I638FSNV

sensitivity

Curated

← predicts response to

DDR2 G505SSNV

sensitivity

Curated

Dasatinib targets …TARGETS15 of 15
→ targets	BCR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FGR	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FRK	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	SRMS	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	LYN	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	HCK	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	BLK	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	YES1	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	LCK	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	SRC	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	FYN	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	KIT	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	EPHA2	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	PDGFRB	—	INHIBITOR	—	1	Curated	chembl	graph →
→ targets	ABL1	—	INHIBITOR	—	1	Curated	chembl	graph →

Dasatinib targets …TARGETS15 of 15

→ targets

BCR

—

INHIBITOR

—

Curated

→ targets

FGR

—

INHIBITOR

—

Curated

→ targets

FRK

—

INHIBITOR

—

Curated

→ targets

SRMS

—

INHIBITOR

—

Curated

→ targets

LYN

—

INHIBITOR

—

Curated

→ targets

HCK

—

INHIBITOR

—

Curated

→ targets

BLK

—

INHIBITOR

—

Curated

→ targets

YES1

—

INHIBITOR

—

Curated

→ targets

LCK

—

INHIBITOR

—

Curated

→ targets

SRC

—

INHIBITOR

—

Curated

→ targets

FYN

—

INHIBITOR

—

Curated

→ targets

KIT

—

INHIBITOR

—

Curated

→ targets

EPHA2

—

INHIBITOR

—

Curated

→ targets

PDGFRB

—

INHIBITOR

—

Curated

→ targets

ABL1

—

INHIBITOR

—

Curated

Dasatinib investigated for …INVESTIGATED_FOR15 of 80show all (up to 200)
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype	supports	A	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Curated	civic	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 5 source records aggregated	supports	B	Chronic Myeloid Leukemia, BCR-ABL1 Positive	5	Curated	civic	graph →
→ investigated for	Neoplasmcancer_family	unknown	4	Neoplasm	1	Curated	chembl	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy	unknown	4	Acute Lymphoblastic Leukemia	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype	unknown	4	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Curated	chembl	graph →
→ investigated for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 13 source records aggregated	supports	C	Chronic Myeloid Leukemia, BCR-ABL1 Positive	13	Curated	civic	graph →
→ investigated for	B Lymphoblastic Leukemia/Lymphomahematologic_malignancy 7 source records aggregated	supports	C	B Lymphoblastic Leukemia/Lymphoma	7	Curated	civic	graph →
→ investigated for	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Likehematologic_malignancy 4 source records aggregated	supports	C	B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Like	4	Curated	civic	graph →
→ investigated for	Acute Lymphoblastic Leukemiahematologic_malignancy 3 source records aggregated	supports	C	Acute Lymphoblastic Leukemia	3	Curated	civic	graph →
→ investigated for	B Acute Lymphoblastic Leukemiahematologic_malignancy	supports	C	B Acute Lymphoblastic Leukemia	1	Curated	civic	graph →
→ investigated for	Lung Squamous Cell Carcinomasubtype	supports	C	Lung Squamous Cell Carcinoma	1	Curated	civic	graph →
→ investigated for	Melanomacancer_family	supports	C	Melanoma	1	Curated	civic	graph →
→ investigated for	Lymphoid Leukemiahematologic_malignancy	unknown	3	Lymphoid Leukemia	1	Curated	chembl	graph →
→ investigated for	Prostate Neoplasmsubtype	unknown	3	Prostate Neoplasm	1	Curated	chembl	graph →
→ investigated for	Acute Myeloid Leukemiahematologic_malignancy	unknown	3	Acute Myeloid Leukemia	1	Curated	chembl	graph →

Dasatinib investigated for …INVESTIGATED_FOR15 of 80show all (up to 200)

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

supports

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

5 source records aggregated

supports

Curated

→ investigated for

Neoplasmcancer_family

unknown

Neoplasm

Curated

Acute Lymphoblastic Leukemia

→ investigated for

Acute Lymphoblastic Leukemiahematologic_malignancy

unknown

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

unknown

Curated

→ investigated for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

13 source records aggregated

supports

Curated

→ investigated for

B Lymphoblastic Leukemia/Lymphomahematologic_malignancy

7 source records aggregated

supports

Curated

→ investigated for

B Lymphoblastic Leukemia/Lymphoma, BCR-ABL1-Likehematologic_malignancy

4 source records aggregated

supports

Curated

Acute Lymphoblastic Leukemia

→ investigated for

Acute Lymphoblastic Leukemiahematologic_malignancy

3 source records aggregated

supports

Curated

→ investigated for

B Acute Lymphoblastic Leukemiahematologic_malignancy

supports

Curated

Lung Squamous Cell Carcinoma

→ investigated for

Lung Squamous Cell Carcinomasubtype

supports

Curated

→ investigated for

Melanomacancer_family

supports

Melanoma

Curated

→ investigated for

Lymphoid Leukemiahematologic_malignancy

unknown

Lymphoid Leukemia

Curated

→ investigated for

Prostate Neoplasmsubtype

unknown

Prostate Neoplasm

Curated

→ investigated for

Acute Myeloid Leukemiahematologic_malignancy

unknown

Acute Myeloid Leukemia

Curated

Dasatinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 208show all (up to 200)
→ investigated in trials for	Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype 37 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	37	Observed	clinicaltrials	graph →
→ investigated in trials for	Leukemia 30 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Leukemia	30	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Lymphoblastic Leukemiahematologic_malignancy 28 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Lymphoblastic Leukemia	28	Observed	clinicaltrials	graph →
→ investigated in trials for	Acute Myeloid Leukemiahematologic_malignancy 16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Acute Myeloid Leukemia	16	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Breast Neoplasm 15 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Breast Neoplasm	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Myeloid Leukemia 15 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Myeloid Leukemia	15	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive 13 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	13	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Prostate Neoplasm 12 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Prostate Neoplasm	12	Observed	clinicaltrials	graph →
→ investigated in trials for	Multiple Myeloma 10 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Multiple Myeloma	10	Observed	clinicaltrials	graph →
→ investigated in trials for	Chronic Lymphocytic Leukemia 8 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Chronic Lymphocytic Leukemia	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Solid Neoplasm 8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Solid Neoplasm	8	Observed	clinicaltrials	graph →
→ investigated in trials for	Malignant Neoplasm 7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Malignant Neoplasm	7	Observed	clinicaltrials	graph →
→ investigated in trials for	B Acute Lymphoblastic Leukemiahematologic_malignancy 6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B Acute Lymphoblastic Leukemia	6	Observed	clinicaltrials	graph →
→ investigated in trials for	B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1 6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1	6	Observed	clinicaltrials	graph →
→ investigated in trials for	Lung Non-Small Cell Carcinoma 6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)	—	—	Lung Non-Small Cell Carcinoma	6	Observed	clinicaltrials	graph →

Dasatinib investigated in trials for …INVESTIGATED_IN_TRIALSderived15 of 208show all (up to 200)

→ investigated in trials for

Chronic Myeloid Leukemia, BCR-ABL1 Positivemolecular_subtype

37 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Leukemia

30 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Leukemia

Observed

Acute Lymphoblastic Leukemia

→ investigated in trials for

Acute Lymphoblastic Leukemiahematologic_malignancy

28 trials (11 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

Acute Myeloid Leukemiahematologic_malignancy

16 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Acute Myeloid Leukemia

Observed

Malignant Breast Neoplasm

→ investigated in trials for

15 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Breast Neoplasm

Observed

→ investigated in trials for

Myeloid Leukemia

15 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Myeloid Leukemia

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ investigated in trials for

13 trials (6 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

Observed

Malignant Prostate Neoplasm

→ investigated in trials for

12 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Malignant Prostate Neoplasm

Observed

→ investigated in trials for

Multiple Myeloma

10 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Multiple Myeloma

Observed

Chronic Lymphocytic Leukemia

→ investigated in trials for

8 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Chronic Lymphocytic Leukemia

Observed

→ investigated in trials for

Solid Neoplasm

8 trials (1 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Solid Neoplasm

Observed

→ investigated in trials for

7 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

→ investigated in trials for

B Acute Lymphoblastic Leukemiahematologic_malignancy

6 trials (4 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

→ investigated in trials for

6 trials (3 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

B Acute Lymphoblastic Leukemia with t(9;22)(q34.1;q11.2); BCR-ABL1

Observed

→ investigated in trials for

6 trials (0 active) · conditions mapped to this cancer only (no hierarchy roll-up)

—

Observed

Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2

Dasatinib studied in …STUDIED_INderived10 of 273show all (up to 200)
→ studied in	NCT02465060Phase 2 · active not recruiting Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 273 trials list this drug (45 active)	—	—	Hematopoietic and Lymphoid Cell Neoplasm,Lymphoma,Malignant Solid Neoplasm+2	1	Observed	clinicaltrials	graph →
→ studied in	NCT06124157Phase 2 · recruiting A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · 273 trials list this drug (45 active)	—	—	B Acute Lymphoblastic Leukemia	1	Observed	clinicaltrials	graph →
→ studied in	NCT02389309Phase 1 · active not recruiting Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors · 273 trials list this drug (45 active)	—	—	Malignant Solid Neoplasm,Brain Neoplasm	1	Observed	clinicaltrials	graph →
→ studied in	NCT07269470Phase 2 · recruiting Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase · 273 trials list this drug (45 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT05007873Phase 2 · active not recruiting ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase · 273 trials list this drug (45 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT03516279Phase 2 · active not recruiting Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 273 trials list this drug (45 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT02689440Phase 2 · active not recruiting Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia · 273 trials list this drug (45 active)	—	—	Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →
→ studied in	NCT01660971Phase 1 · active not recruiting Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery · 273 trials list this drug (45 active)	—	—	Pancreatic Carcinoma,Pancreatic Adenocarcinoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT02559778Phase 2 · recruiting Pediatric Precision Laboratory Advanced Neuroblastoma Therapy · 273 trials list this drug (45 active)	—	—	Neuroblastoma	1	Observed	clinicaltrials	graph →
→ studied in	NCT07804901Phase 2 · not yet recruiting Asciminib Frontline Risk Adapted · 273 trials list this drug (45 active)	—	—	Chronic Myeloid Leukemia, BCR-ABL1 Positive	1	Observed	clinicaltrials	graph →

Dasatinib studied in …STUDIED_INderived10 of 273show all (up to 200)

→ studied in

NCT02465060Phase 2 · active not recruiting

Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) · 273 trials list this drug (45 active)

—

Observed

→ studied in

NCT06124157Phase 2 · recruiting

A Study Testing the Combination of Dasatinib or Imatinib to Chemotherapy Treatment With Blinatumomab for Children, Adolescents, and Young Adults With Philadelphia Chromosome Positive (Ph+) or ABL-Class Philadelphia Chromosome-Like (Ph-Like) B-cell Acute Lymphoblastic Leukemia (B-ALL) · 273 trials list this drug (45 active)

—

Observed

Malignant Solid Neoplasm,Brain Neoplasm

→ studied in

NCT02389309Phase 1 · active not recruiting

Dasatinib, Temsirolimus, and Cyclophosphamide in Treating Patients With Advanced, Recurrent, or Refractory Solid Tumors · 273 trials list this drug (45 active)

—

Observed

→ studied in

NCT07269470Phase 2 · recruiting

Phase II Study Assessing the Safety and Efficacy of Dasatinib in Combination With Ropeginterferon in Patients With Newly Diagnosed Chronic Myeloid Leukemia in Chronic Phase · 273 trials list this drug (45 active)

—

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ studied in

NCT05007873Phase 2 · active not recruiting

ASTX727 and Dasatinib for the Treatment of Newly Diagnosed Philadelphia Chromosome or BCR-ABL Positive Chronic Myeloid Leukemia in Chronic Phase · 273 trials list this drug (45 active)

—

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive

→ studied in

NCT03516279Phase 2 · active not recruiting

Pembrolizumab and Dasatinib, Imatinib Mesylate, or Nilotinib in Treating Patients With Chronic Myeloid Leukemia and Persistently Detectable Minimal Residual Disease · 273 trials list this drug (45 active)

—

Observed

Chronic Phase Chronic Myeloid Leukemia, BCR-ABL1 Positive,Chronic Myeloid Leukemia, Philadelphia Chromosome Positive, BCR-ABL1 Positive

→ studied in

NCT02689440Phase 2 · active not recruiting

Dasatinib and Venetoclax in Treating Patients With Philadelphia Chromosome Positive or BCR-ABL1 Positive Early Chronic Phase Chronic Myelogenous Leukemia · 273 trials list this drug (45 active)

—

Observed

Pancreatic Carcinoma,Pancreatic Adenocarcinoma

→ studied in

NCT01660971Phase 1 · active not recruiting

Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery · 273 trials list this drug (45 active)

—

Observed

→ studied in

NCT02559778Phase 2 · recruiting

Pediatric Precision Laboratory Advanced Neuroblastoma Therapy · 273 trials list this drug (45 active)

—

Neuroblastoma

Observed